Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer

NCT02494921 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.

NCT NCT02494921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02494921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer
Lead sponsor
Rahul Aggarwal
Phase
Phase 1/2
Overall status
Completed
Start date
November 20, 2015
Completion date
July 30, 2021
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer